TY - JOUR
TI - The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant acinetobacter baumannii: A systematic review of clinical evidence
AU - Fragkou, P.C.
AU - Poulakou, G.
AU - Blizou, A.
AU - Blizou, M.
AU - Rapti, V.
AU - Karageorgopoulos, D.E.
AU - Koulenti, D.
AU - Papadopoulos, A.
AU - Matthaiou, D.K.
AU - Tsiodras, S.
JO - Microorganisms
PY - 2019
VL - 7
TODO - 6
SP - null
PB - MDPI AG
SN - null
TODO - 10.3390/microorganisms7060159
TODO - null
TODO - Treatment options for multidrug resistant Acinetobacter baumannii strains (MDR-AB) are limited. Minocycline has been used alone or in combination in the treatment of infections associated with AB. A systematic review of the clinical use of minocycline in nosocomial infections associated with MDR-AB was performed according to the PRISMA-P guidelines. PubMed-Medline, Scopus and Web of Science™ databases were searched from their inception until March 2019. Additional Google Scholar free searches were performed. Out of 2990 articles, 10 clinical studies (9 retrospective case series and 1 prospective single center trial) met the eligibility criteria. In total, 223 out of 268 (83.2%) evaluated patients received a minocycline-based regimen; and 200 out of 218 (91.7%) patients with available data received minocycline as part of a combination antimicrobial regimen (most frequently colistin or carbapenems). Pneumonia was the most common infection type in the 268 cases (80.6% with 50.4% ventilator-associated pneumonia). The clinical and microbiological success rates following minocycline treatment were 72.6% and 60.2%, respectively. Mortality was 20.9% among 167 patients with relevant data. In this systematic review, minocycline demonstrated promising activity against MDR-AB isolates. This review sets the ground for further studies exploring the role of minocycline in the treatment of MDR-AB associated infections. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.
ER -